盐酸埃克替尼治疗终末期非小细胞肺癌的临床观察  

Clinical Observation of Icotinib Hydrochloride for Patients with End-stage Non-small Cell Lung Cancer

作　　者：曾越灿[1,2] 邢锐[1] 迟峰[1] 吴荣[1] 蔡炜嵩[1] 肖玉平[2] 辛彦[2] 王乃乾[2] 

机构地区：[1]中国医科大学附属盛京医院肿瘤科,沈阳110022 [2]中国医科大学附属第一医院第四肿瘤研究所,沈阳110001

出　　处：《医学研究杂志》2014年第2期19-22,共4页Journal of Medical Research

基　　金：国家自然科学基金资助项目(81201803)

摘　　要：目的探讨盐酸埃克替尼对终末期(PS评分≥3分)非小细胞肺癌的疗效。方法回顾性分析终末期非小细胞肺癌患者50例,27例接受盐酸埃克替尼治疗,23例不接受盐酸埃克替尼治疗和其他放化疗。结果疾病控制率:治疗组是85.2%,对照组是26.1%(P<0.001)。治疗组中位生存期为102天,对照组中位生存期为65天(P=0.008)。结论盐酸埃克替尼可延长终末期非小细胞肺癌患者的生存期,提高疾病控制率。Objective To explore the efficacy of icotinib hydrochloride in the treatment of patients with end - stage（PS score /〉3 points） non - small cell lung cancer. Methods A retrospective study ws performed. Fifty patients with end - stage non - small cell lung cancer were divided into two groups： the treatment group （27 patients） and the control group（ 23 patients）. Patients in the treatment group received icotinib hydrochloride treatment,and those in the control group did not receive icotinib hydrochloride treatment and any other che- moradiotherapy. Results In this study, disease control rate was 85.2% in the control group and was 26.1% in the control group（P 〈 0. 001 ） ; the median survival time was 102 days in the treatmnet group and was 65 days in the control group（P = 0. 008）. Conclusion Icotinib hydrochloride could improve the survival and disease control rate for patients with end - stage non - small cell lung cancer.

关 键 词：盐酸埃克替尼 非小细胞肺癌 靶向治疗 

分 类 号：R737[医药卫生—肿瘤]